Clinical Trial Update: Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and tolerability of OXC XR as adjunctive therapy in adults with refractory partial epilepsy; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• OXC XR (oxcarbazepine extended-release)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Partial Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2017-05-31